LabCorp to buy Clearstone to build Asia Pacific presence

By Gareth Macdonald

- Last updated on GMT

Related tags Mergers and acquisitions

LabCorp will buy Clearstone Central Labs in a deal that cements the firms’ existing clinical trial-focused collaboration.

The deal, which is expected to close this quarter, would add Clearstone’s capabilities laboratory analysis for late-stage clinical research and geographic reach to LabCorp’s strengths in North America.

LabCorp CEO David King said: "This transaction is an important milestone as it extends our global footprint and service capabilities in key geographies such as Asia Pacific, and advances the Company's companion diagnostics and personalized medicine strategy​.”

This was echoed by Clearstone CEO Lewis Cameron, who explained that the acquisition builds on an existing collaboration​ between the two contract services firms.

Clearstone has already been working closely with LabCorp’s Esoterix division under a strategic collaboration agreement, which has resulted in a number of client success stories. We will now be a single team that is completely focused on exceeding our customer’s drug development objectives​.”

News of the deal comes at a busy time of mergers and acquisitions in the contract research sector. In the last few weeks alone inVentiv health has unveiled plans to buy PharmaNet​ and INC said it is going to buy Kendle​.

Orchid deal smells less sweet?

LabCorp’s plans for Clearstone follow just days after the US testing organisation extended its offer for UK DNA analysis firm Orchid Cellmark.

In a press release on May 18 LabCorp said it received a request from the Federal Trade Commission for additional information under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, applicable to the acquisition of Orchid.

LabCorp also said it will cooperate with the FTC's request for additional information.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us


View more